MOD GRF 1-29 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
=== Cell cycle === TGF-β plays a crucial role in the regulation of the cell cycle by blocking progress through G1 phase. TGF-β causes synthesis of p15 and p21 proteins, which block the cyclin:CDK complex responsible for retinoblastoma protein (Rb) phosphorylation. Thus, TGF-β blocks advancement through the G1 phase of the cycle. In doing so, TGF-β suppresses expression of c-myc, a gene which is involved in G1 cell cycle progression.
Abiotrophy (loss in vitality of organ or tissue) Atrophy (reduced functionality of an organ, with decrease in the number or volume of cells) Hypertrophy (increase in the volume of cells or tissues) Hypotrophy (decrease in the volume of cells or tissues) Dystrophy (any degenerative disorder resulting from improper or faulty nutrition) Pseudohypertrophy (false enlargement of muscle)
In 2016, General Electric announced a sCO2-based turbine that enabled a 50% efficiency of converting heat energy to electrical energy. In it the CO2 is heated to 700 °C. It requires less compression and allows heat transfer. It reaches full power in 2 minutes, whereas steam turbines need at least 30 minutes. The prototype generated 10 MW and is approximately 10% the size of a comparable steam turbine. The 10 MW US$155-million Supercritical Transformational Electric Power (STEP) pilot plant was completed in 2023 in San Antonio. It is the size of a desk and can power around 10,000 homes. In 2025, The Nuclear Power Institute of China (NPIC) of the China National Nuclear Corporation (CNNC) and its partners have commissioned the world's first commercial supercritical CO2 system - Chaotan One - with a capacity of 2 x 15 MW, utilizing waste heat from a steel factory in Liupanshui, Guizhou Province.
Olivia Thirlby as Cassandra Anderson:A rookie Judge and genetic mutant with powerful psychic abilities. Anderson can sense the thoughts and emotions of others. Thirlby contrasted her character with Dredd's "black and white" perspective, describing Anderson as existing "in a grey area where everything is enhanced or clouded by the fact [that] she knows what is going on in the very interior of a person". She undertook weapons and combat training, learning to perform a roundhouse kick to make her believably physically commanding. The character was partially inspired by singer Debbie Harry. Lena Headey as Madeline "Ma-Ma" Madrigal: A former prostitute turned drug lord and criminal kingpin who is the sole supplier of "Slo-Mo", a new and addictive drug. Headey's performance was inspired by punk-rock singer Patti Smith. Reich described the character as someone who does "not care at all about what anybody thinks or feels and she will do, and behave, as she wants". Headey said: "I think of [Ma-Ma] like an old great white shark who is just waiting for someone bigger and stronger to show up and kill her ... she's ready for it. In fact, she can't wait for it to happen ... She's an addict, so she's dead in that way, but that last knock just hasn't come." Before Headey's casting, the character was envisioned as a heavily made-up, scarred and obese older woman. Wood Harris as Kay: Ma-Ma's clansman. Harris described the character as a villain, but one that sees himself as no worse than the Judges. Harris said: " ...
Sources: en.wikipedia.org
== Early life == He was born in Fort Worth, Texas, on 15 July 1921, the only son of George E. Merrifield and Lorene née Lucas. In 1923 the family moved to California where he attended nine grade schools and two high schools before graduating from Montebello High School in 1939. It was there that he developed an interest both in chemistry and in astronomy. After two years at Pasadena Junior College he transferred to the University of California at Los Angeles (UCLA). After graduation in chemistry he worked for a year at the Philip R. Park Research Foundation taking care of an animal colony and assisting with growth experiments on synthetic amino acid diets. One of these was the experiment by Geiger using the law of the minimum that first demonstrated that the essential amino acids must be present simultaneously for growth to occur. He returned to graduate school at the UCLA chemistry department with professor of biochemistry M.S. Dunn to develop microbiological methods for the quantitation of the pyrimidines. The day after graduating on 19 June 1949, he married Elizabeth Furlong and the next day left for New York City and the Rockefeller Institute for Medical Research.
Dalman et al. (2024) proposed the new name Tyrannosaurus mcraeensis for the holotype (NMMNH P-3698), referencing the McRae Group, the rock layers to which the Hall Lake Formation belongs. The holotype of T. mcraeensis is found in the strata that are around a few million years older than the accepted range of T. rex, which existed at the end of the Maastrichtian. The rock layers were initially estimated to date to between 72.7 and 70.9 Ma, correlating to the latest Campanian or earliest Maastrichtian. However, in a 2024 conference abstract, the specific stratigraphic layer which yielded T. mcraeensis was estimated to be younger than 69.0 ± 0.4 Ma and older than 66.0 Ma based on the sandstone from the same fossil locality, which would suggest that the age of T. mcraeensis is much closer to T. rex than previously thought. T. mcraeensis was estimated at 12 metres (39 ft) long, which is similar to the size of an adult T. rex. The two are distinguished by characters of the skull. Amongst these, the dentary of T. mcraeensis is proportionately longer and possesses a less prominent chin, and the lower jaw shallower than that of T. rex, suggesting a weaker bite. The teeth are likewise blunter and more laterally compressed, while the post orbital crests are less prominent. Likewise, the skeletal anatomy showcases shared characteristics with Tarbosaurus and Zhuchengtyrannus. The validity of T. mcraeensis was questioned by other researchers in 2025. Morrison and colleagues noted the uncertainty in the previous age estimate and argued that the inclusion of the titanosaurian fossil (cf.
== External links == GeneReviews/NCBI/NIH/UW entry on Cystinosis Human CTNS genome location and CTNS gene details page in the UCSC Genome Browser. Genetics Home Reference page on CTNS. Genetic Testing Registry.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.